钒酸钠
钒酸钠 性质
| 熔点 | 850-866 °C(lit.) |
|---|---|
| 储存条件 | Sealed in dry,Room Temperature |
| 溶解度 | 可溶于水中 |
| 形态 | 固体 |
| 颜色 | 米白色 |
| 生物来源 | synthetic (organic) |
| 水溶解性 | soluble |
| 暴露限值 | NIOSH: Ceiling 0.05 mg/m3 |
| 稳定性 | 稳定的。与强氧化剂不相容。 |
| InChI | InChI=1S/3Na.4O.V |
| InChIKey | HQHUIUQMQXUPHI-UHFFFAOYSA-N |
| SMILES | [V](=O)(O[Na])(O[Na])O[Na] |
| CAS 数据库 | 13721-39-6(CAS DataBase Reference) |
| EPA化学物质信息 | Sodium vanadium oxide (Na3VO4) (13721-39-6) |
钒酸钠 用途与合成方法
PPTPase.
In the presence of oxidizing agents vanadium ions exist as the hydrated monomer of Sodium orthovanadate (vanadate: HVO4 2- or H2VO 4- ) at micromolar concentations near neutral pH. Sodium orthovanadate (vanadate) also begins to polymerize at concentrations greater than 0.1 mM at neutral pH. The yellow-orange solutions of decavanadate can be converted to the colorless solutions of monomeric Sodium orthovanadate (vanadate) by dilution after a period of many hours. The process is hastened by boiling at pH 10, which encourages the kinetically sluggish depolymerization process. Sodium orthovanadate could alter the phosphorylation status of ASK1 at serine 83 and threonine 845 induced by ischemia. Sodium orthovanadate could increase the tyrosine posphorylation of PTEN and further inhibit the activation of ASK1 via activating Akt during cerebral ischemia.
安全信息
| 危险品标志 | Xn |
|---|---|
| 危险类别码 | 20/21/22 |
| 安全说明 | 22-36 |
| 危险品运输编号 | UN3285 |
| WGK Germany | 3 |
| RTECS号 | YW1120000 |
| TSCA | TSCA listed |
| 危险等级 | 6.1 |
| 包装类别 | III |
| 海关编码 | 28419030 |
| 存储类别 | 13 - 不可燃性固体 |
| 危险性类别 | 急性毒性 类别4 经皮 急性毒性 类别4 吸入 急性毒性 类别4 经口 眼部刺激 类别2 经皮刺激 类别2 |
MSDS信息
钒酸钠 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2026-03-03 | 081104 | 原钒酸钠, 99.9% (metals basis) | 13721-39-6 | 500g | 11372 |
| 2026-03-03 | 20533 | 原钒酸钠(99%) | 13721-39-6 | 250g | 4361 |
